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Abstract 
We present a case report of a 42 year old female, diagnosed at the age of 3 with Juvenile Dermatomyositis. The clinical course was 
severe and refractory to immunosuppressive therapy. Currently, she is mostly affected by severe muscle atrophy, large joint contractures, 
calcinosis, and a lipodystrophy associated metabolic syndrome with hypertriglyceridemia, insulin resistance, high total testosterone and hepatic 
steatosis. She developed Hodgkins´ lymphoma in the course of her disease. Personalized therapeutic choices are discussed as regards juvenile 
dermatomyositis complications. 
© 2018 Elsevier B.V. All rights reserved. 




































Juvenile dermatomyositis (JDM) is an autoimmune dis-
ase resulting in perivascular inflammation, perifascicular at-
ophy and muscle degeneration [1,2] and represents 85%
f the idiopathic inflammatory myopathies in childhood [3] .
ovel autoantibodies associated to specific clinical pheno-
ypes have been described in the past decade. Amongst these,
nti-p155/140 – targeted to transcriptional intermediary factor
 gamma (TIF1- γ ) and anti-p140 – targeted to nuclear matrix
rotein 2 (NXP2), are more likely to occur in children with
alcinosis and cutaneous ulceration [4–6] . 
Fifty years ago, active treatment of childhood onset JDM
esulted in much improved prognosis [7] . Despite progress,
tandard of care still remains confined to untargeted immuno-
uppressive therapy with steroids [8] . As recently reviewed
9] , the use of steroid sparing agents is recommended, usu-
lly with methotrexate, but also azathioprine and cyclosporine,∗ Corresponding author. 
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960-8966/© 2018 Elsevier B.V. All rights reserved. ntravenous immune globulin, tacrolimus, rituximab and cy-
lophosphamide in refractory cases. Cardiac or respiratory in-
olvement lower 10–year survival rates, otherwise reported
o be over 90% [10,11] . Many children therefore survive to
dulthood, but there are scarce descriptions of disease activ-
ty, co-morbidities and functional status after prolonged dis-
ase. Aiming to contribute to disease knowledge we report
n adult patient with JDM exhibiting lipodystrophy, ongo-
ng calcinosis, and irreversible joint contractures, in whom
 prior diagnosis of malignancy restricts therapeutic choices
nd whose management remains an ongoing challenge. 
. Case report 
The female patient, currently 42 years-old, was admitted
o the Hammersmith Hospital in London, at the age of 3. At
hat time, major complaints were proximal muscle weakness
ith Gowers sign, unilateral facial nerve palsy and ulcerat-
ng skin lesions ( Fig. 1 a–d). The electromyography of right
eltoid, triceps and tibialis anterior muscles revealed short,
mall amplitude polyphasic potentials, with no spontaneous
ctivity at rest. The diagnosis of JDM was made on the ba-
is of needle biopsy of left quadriceps displaying vacuolar
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Fig. 1. Dermatomyositis; vasculitic ulcers; recurrent contractures. This girl was first seen at 3 years of age with an 8-month history of weakness, skin rash 
and misery, with progressive flexion contractures of the hips (a) and knees (b). She responded well to steroids and was rehabilitated with active physiotherapy. 
She was readmitted from abroad 8 months later with marked vasculitic ulcers in the axillae, which gradually resolved (c) and (d). She later had recurrent 
relapses and remissions with adjustment of therapy. At 7 years of age she stopped walking after formation of a large haematoma in the right thigh. She was 
again rehabilitated with active physiotherapy (e). There was still active skin rash and some facial weakness with limited eye closure (f). She was still ambulant 
15 months later but had considerable weakness and fixed equinus (g). She had lost weight and had very little muscle bulk. Text and Images reproduced with 











i  appearance of several muscle fibers and perifascicular atro-
phy (Supplementary Fig. 1). 
From the time of diagnosis, treatment consisted of a steroid
regimen, initially given alone and subsequently combined
with azathioprine, followed by cyclosporine. From the on-
set of the illness, periods of immobility were followed byajor joint contractures and over the next few years she was
egularly admitted to hospital for periods of intensive phys-
otherapy which were extremely successful ( Fig. 1 e–g). Of
ote, there was no history of consanguinity, episodic fevers,
eizures, anemia, respiratory difficulties or learning disabil-
ties and she successfully completed a university degree.
















































































































m  verall, response to treatment was poor and by the age of
1 she was wheelchair bound and immunosuppressive therapy
as stopped. Even though the episodes of cutaneous ulcera-
ion no longer occurred, several other features developed over
he next years namely an erythematous pruritic and progres-
ively more indurated facial skin, generalized calcinosis and
ntermittent diarrhea, the latter attributed to intestinal bacterial
vergrowth syndrome. Nodular-Sclerosis Classical Hodgkin 
ymphoma (stage II, supra-diaphragmatic, category B) was
iagnosed at age 31, with full remission after six cycles
f chemotherapy consisting of doxorubicin, bleomycin, vin-
lastin and dacarbazine. There was no serological evidence
f acute Epstein-Barr virus infection (virological status in
ymphoma cells was not evaluated). She did not tolerate a
yproterone/ethinylestradiol combination pill due to dysmen- 
rrhoea. 
At the age of 38 she was re-evaluated in our Autoimmune
iseases Unit. She complained of menstrual irregularities, hir-
utism and relentless calcinosis. She exhibited low stature,
iffuse alopecia, poikiloderma in a photosensitive distribu-
ion, symmetric parotid hypertrophy, periungueal telangiecta- 
ia, livedo reticularis (over the trunk and anterior thighs) and
ultiple atrophic scars corresponding to areas of previous ul-
eration. There were fixed contractures of the major joints
shoulders, elbows and knees), lumbar scoliosis, generalized
uscle atrophy and multiple foci of calcinosis along the mus-
le fascia of limbs and trunk. The abdomen was dispropor-
ionately large and corresponded to a most striking lipodys-
rophy with absence of fat in the face and limbs ( Fig. 2 ).
here was no cervical weakness, no difficulty in speaking or
n swallowing. She was able to move her upper limbs, pick
p small objects and feed herself. 
Laboratory evaluation revealed normal creatine kinase and
ldolase, increased total serum testosterone of 71 ng/dL, (nor-
al values 10,8–56,9 ng/dL), but normal levels of serum thy-
oid stimulating hormone, prolactin, androstenedione, basal
7-hydroxy progesterone, estradiol, FSH, LH, ACTH and
erum cortisol levels. Her fasting plasma glucose (69 mg/dL)
nd Peptide C (6,5 ng/mL, normal range 0,9–7.1 ng/mL)
ere normal but insulin was increased to 65,5 uUI/mL
normal range 1,9–23 uUI/mL). She also had hypertriglyc-
ridemia (1860 mg/dL, normal range < 150 mg/dL) and low
evels of high density lipoprotein cholesterol (28 mg/dL, nor-
al range < 130 mg/dL). Liver transaminases were normal but
he gamma-glutamyl transferase was 3 fold elevated; ANA
esting was intermittently positive, with a low title (1/160) but
o specific positivity was found; there was no lung parenchy-
al change in the chest radiograph which displayed multi-
le calcifications in the subcutaneous tissues; the echocar-
iogram was normal; no structural abnormality or pressure
hanges were detected by Doppler echocardiography and nail-
old video-capilaroscopy revealed a late-scleroderma pattern
Supplementary Fig. 2). Magnetic resonance imaging (MRI)
howed diffuse muscle fatty atrophy (Grade III–IV) of mas-
eters, shoulder girdle, deltoids, paravertebral thoracic, gluteal
nd thigh groups. The only relatively preserved muscles lo-
alized to the neck, thighs (adductor magnus and vastus in-ermedius) and legs (tibialis anterior and posterior and toe ex-
ensors). There was no sign of muscle inflammation on fluid
ensitive sequences (STIR and T2-weighted images). Parotid
lands were heterogeneous with fatty infiltrates and diffuse
alcifications. There was a marked increase in posterior cer-
ical, axillary, mediastinal and intra-peritoneal fat deposition,
lso asymmetrically localized to the anterior and lateral por-
ion of both thighs ( Fig. 3 ). Small areas of subcutaneous
edema were suggestive of panniculitis in thighs and legs.
epatomegaly was noted with splenomegaly, normal kidneys,
terus and ovaries. There was no lymphadenopathy. No mu-
ations were found in the genes LMNA, ZMPSTE24, PTRF,
AV-1, AGPAT2, BSCL2, PPARG, INSR, PLIN1, CIDEC,
IK3R1, NSMCE2, POC1A, PCYT1A, POLD1 or PSMB8 .
oon after the genetic tests were performed, the patients´
erum tested positive for anti-transcriptional intermediary fac-
or gamma protein antibody (TIF1-gamma) (Euroimmun ®-
übeck, Euroline scan software, patient intensity 15, control
9), supporting the original diagnosis. There was no reactiv-
ty against the following antigens: Mi-2 (nucleosome remod-
ling deacetyalse complex), MDA (melanoma-differentiation 
ssociated gene 5), SRP (54 kDa, signal recognition parti-
le), NXP-2, SAE (small-ubiquitin-like modifier activating en-
yme), Ku, PM-Scl (75 and 100 kDa), Jo-1 (histidyl-tRNA
ynthetase), PL-7 (threonyl-tRNA synthetase), PL-12 (alanyl- 
RNA synthetase), EJ protein (glycyl-tRNA synthetase), OJ
isoleucyl-tRNA synthetase) and Ro-52KD. 
Following re-assessment, weekly s.c. methotrexate (up to
0 mg/week) and quarterly i.v. Pamidronate failed to have
 positive impact on the rate of calcinosis deposits and
ange of metabolic abnormalities. The latter was associated
ith an episode of renal colic and both were discontin-
ed after two years. Since then, painful calcium deposits
ave been removed surgically on three occasions. She has
ot tolerated metformin due to side-effects and is poorly
ompliant with fenofibrate. Decreased gastrointestinal ab- 
orption may also contribute to a poor response to ther-
py and serum triglyceride concentrations are usually 5–6
old elevated. She reports beneficial anti-diarrheal effects with
SL#3 ®, a commercially available probiotic, taken as re-
uired. Apart from feeling that the skin around her face is
ighter there has been no change in her clinical features over
he past four years. She is partially dependent for her hygiene
eeds which restrict her social life but is otherwise indepen-
ent in her daily activities with an electric wheelchair and
dapted motorized vehicle. She undertakes physiotherapy ses-
ions consisting of passive limb mobilization three times per
eek. 
. Discussion 
JDM is a very rare condition with an incidence of 2–4
ases per million per year, mostly affecting females. In so
uch as the peak incidence occurs between the ages of 5–
0, up to 25% of patients experience disease onset before the
ge of 4 [12] , similarly to our patient. The disease may re-
it, relapse or follow a chronic continuous form [13] . When
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Fig. 2. Clinical features of the patient as an adult: poikiloderma and skin tightness (a); parotid hypertrophy (b); livedo reticularis over dorsum (c); atrophic 
scars (d); periungueal telangiectasia (e); hirsutism (f); calcinosis in fascial planes and joint contractures (g); cutaneous calcinosis (h); lipodystrophy with 
abdominal redistribution of fat and muscle atrophy (i). 
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Fig. 3. MRI T1-weighted axial images from the abdomen (a) and thigh (b), from a healthy subject (1) and from the patient (2) where the massive increase 



























































n  ompared with adult auto-antibody reactivities, anti-TIF1- γ
ositive children are more frequently affected by muscle atro-
hy, contractures, calcinosis and cutaneous vasculitis [14] . Of
ote, our patient received appropriate therapy, namely steroids
nd cyclosporine from disease onset. Physiotherapy treatments
ere intense but intermittent, with prolonged periods of im-
obility. Recurrent contractures developed from early on in
he course of disease. 
Several complex complications developed as disease
rogressed. Lymphoma developed in adulthood, many years
fter disease onset. In a recent literature review lymphoma
as very rarely diagnosed in juvenile dermato/polymyositis,
ccurred only after the disease was well established and
ll the patients suffered from the non-Hodgkins´ lymphoma
ype [15] . Hodgkin lymphoma (HL) has been described in
on-immunosuppressed individuals but HL-like conditions 
ave also been described in the spectrum of post-transplant
ymphoproliferative disorders [16] . After a ten year-lapse, a
elationship to prior immunosuppressive therapy remains an
lusive possibility in our patient. 
Albeit not confirmed, the initial lack of an auto-antibody
arker, the presence of marked lipodystrophy, possible pan-
iculitis and lack of muscle inflammation in the biopsy speci-
en reviewed raised the suspicion of an alternative diagnosis
ut no evidence of an auto-inflammatory disorder or a muscle
ystrophy was found. While the lipodystrophy was suggestive
f Chronic Atypical Neutrophilic Dermatosis with Lipodys-
rophy and Elevated temperatures (CANDLE) [17,18] , lack
f periodic fevers and systemic inflammation made this lessikely, whereas the presence of anti-TIF1- γ , muscle atrophy,
oint contractures, calcinosis and nailfold changes clinched
he diagnosis of JDM. 
JDM occurs in genetically susceptible patients [19–22] .
ts association with lipodystrophy (deposition of fat in ec-
opic locations such as in salivary glands, the peritoneal cav-
ty, liver and muscle and absence of fat deposits in other
ites) [23,24] and lipodystrophy-associated metabolic abnor- 
alities (hypertriglyceridemia, insulin resistance, high testos-
erone, hypertrichosis and probable fatty liver disease) has
een described with severe calcinosis, joint contractures, mus-
le atrophy, chronic continuous illness course, facial erythema
nd anti-TIF1- γ positivity [25,26] , all of which were present
n our patient. 
Follow up of JDM patients into adulthood has demon-
trated the overall systemic nature of the disease and its im-
act on several organs on the long term. Even though studies
n a Norway cohort followed over 16,8 years (2–38,1 years)
as showed JDM patients often maintain active disease in
he long term, our patient mostly suffers from cumulative or-
an damage, whose main predictor is disease activity at onset
27] . 
Because of the loss of adipose tissue, levels of the
dipocyte-secreted hormone leptin may be low and leptin re-
lacement could be a therapeutic option in our patient, in an
ttempt to overcome morphological and metabolic abnormali-
ies. However lymphoma after leptin therapy for patients with
cquired lipodystrophy has been described [28] . In addition,
o single drug or associations of drugs has been effective in


























































































 the treatment of calcinosis in JDM [29] . Upregulation of type
I interferon pathway, described as a biomarker of JDM dis-
ease activity [30] as well as an effector molecule in CANDLE
[31] , may be a driver of disease pathogenesis. It is tempting
to speculate that antagonizing type I interferon could have
a favorable therapeutic impact in our patient. Overall, a his-
tory of lymphoma, longstanding immune-mediated disease, a
potentially vulnerable immune system and the degree of irre-
versible organ damage lead us to take a conservative “do no
harm” approach. 
In conclusion we present a patient with a diagnosis of
JDM at the age of 3 years, with a partial response to therapy
and several co-morbidities. Marked lipodystrophy and little
inflammation in the original muscle biopsy specimen raised
suspicion of an overlap with muscle dystrophy which was
not confirmed. Our key message highlights the extraordinary
advances introduced in the 1980s´, reducing patient mortality
and side-effects of extremely high dosages of steroids. De-
spite the presence of disability our patient survived a severe
childhood disease and leads a meaningful life. 
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